What may and may not be feasible to minimize the worsening of geographic atrophy

References

• Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. the international arm epidemiology study group. Surv Ophthalmol 1995;39:367-74
   PubMed Web of Science ®Google Scholar
• Buch H, Vinding T, Nielsen NV, et al. 14-year incidence progression and visual morbidity of age-related maculopaty: The Copenhagen City Eye Study. Ophthalmology 2005;112:787-98
   PubMedGoogle Scholar
• Suness JS, Margalit E, Bressler NM, et al. The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials. Ophthalmology 2007;114:271-7
   PubMedGoogle Scholar
• Suness JS, Gonzalez-Baron J, Bressler NM, et al. The development of choroidal neovascularization in eyes with geographic atrophy form of age-related macular degeneration. Ophthalmology 1999;106:910-19
   PubMedGoogle Scholar
• Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration: A case-control study in the age-related eye disease study: AREDS report n 3. Ophthalmolgy 2000;107:2224-32
   PubMed Web of Science ®Google Scholar
• Age-Related Eye Disease Study Research Group. Risk factors for the incidence of advanced age-related macular degeneration in age-related eye disease study: AREDS report n 8. Arch Ophthalmol 2008;119:1417-36
   Google Scholar
• Brunk UT, Terman A. Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free RadicBiol Med 2002;33:611-19
   PubMed Web of Science ®Google Scholar
• Mata NL, Lichter JB, Vogel R, et al. Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina 2013;33:498-507
   PubMed Web of Science ®Google Scholar
• Kubota R, Al-Fayoumi S, Mallikaarjun S, et al. Phase I, dose-ranging study of emixustat hydrochloride (ACU-4429), a novel visual cycle modulator, in healthy volunteers. Retina 2014;34:603-9
   PubMed Web of Science ®Google Scholar
• Dugel P, Novack R, Csaky K, et al. A Phase 2 Double-masked, Placebo-controlled, Dose Ranging Study of Emixustat Hydrochloride (ACU-4429) in Subjects with GA Associated with Dry AMD. Invest Ophthalmol Vis Sci 2013;54:E-Abstract 4506
   Google Scholar
• Safety and efficacy assessment treatment trials of emixustat hydrochloride (SEATTLE). Available from: https://clinicaltrials.gov/ct2/show/NCT01802866
   Google Scholar
• Anderson DH, Mullins RF, Hageman GS, et al. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002;134:411-31
   PubMed Web of Science ®Google Scholar
• Gehrs KM, Jackson JR, Brown EN, et al. Complement, age-related macular degeneration and a vision of the future. Arch Ophthalmol 2010;128:349-58
   PubMedGoogle Scholar
• Fluocinolone acetonide intravitreal inserts in geographic atrophy. Available from: https://clinicaltrials.gov/ct2/show/NCT00695318
   Google Scholar
• Potentia. Available from: www.potentiapharma.com/about/news.htm
   Google Scholar
• Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology 2014;121:693-701
   PubMed Web of Science ®Google Scholar
• Intravitreal LFG316 in patients with age-related macular degeneration (AMD). Available from: https://clinicaltrials.gov/ct2/show/NCT01527500
   Google Scholar
• A study investigating the safety and efficacy of lampalizumab intravitreal injections in patients with geographic atrophy secondary to age-related macular degeneration (SPECTRI). Available from: https://clinicaltrials.gov/ct2/show/NCT02247531
   Google Scholar
• A study investigating the efficacy and safety of lampalizumab intravitreal injections in patients with geographic atrophy secondary to age-related macular degeneration (CHROMA). Available from: https://clinicaltrials.gov/ct2/show/NCT02247479
   Google Scholar
• Sirolimus for advanced age-related macular degeneration (SIRGA2). Available from: www.clinicaltrials.gov/ct2/show/NCT01445548
   Google Scholar
• Wang J, Ohno-Matsui K, Yoshida T, et al. Amyloid-β up-regulates complement factor B in retinal pigment epithelial cells through cytokines released from recruited macrophages/microglia: another mechanism of complement activation in age-related macular degeneration. J Cell Physiol 2009;220:119-28
   PubMed Web of Science ®Google Scholar
• Efficacy, safety and tolerability study of rn6g in subjects with geographic atrophy secondary to age-related macular degeneration. Available from: https://clinicaltrials.gov/ct2/show/NCT01577381
   Google Scholar
• Grunwald JE, Metelitsina TI, Dupont JC, et al. Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci 2005;46:1033-08
   PubMed Web of Science ®Google Scholar
• Safety study of a topical treatment for dry age related macular degeneration. Available from: www.clinicaltrials.gov/ct2/show/NCT01922128
   Google Scholar
• Phase II/III study of the efficacy and safety of MacuCLEAR MC-1101 in treating dryage-related macular degeneration (McCP2/3). Available from: https://clinicaltrials.gov/ct2/show/NCT02127463
   Google Scholar
• WoldeMussie E, Ruiz G, Wijono M, et al. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001;42:2849-55
   PubMed Web of Science ®Google Scholar
• Wheeler L, WoldeMussie E, Lai R. Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol 2003;48(suppl 1):S47-51
   PubMed Web of Science ®Google Scholar
• Tao W, Wen R, Goddard MB, et al. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci 2002;43:3292-8
   PubMed Web of Science ®Google Scholar
• Zhang K, Hopkins JJ, Heier JS, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci USA 2011;108:6241-5
   PubMed Web of Science ®Google Scholar